TOPIGEN Pharmaceuticals Inc. signs development and manufacturing agreement with The Dow Chemical Company


TOPIGEN Pharmaceuticals Inc. and The Dow Chemical Company recently signed a joint agreement for Dowpharma, Dow's pharmaceutical manufacturing services business unit, to supply select, proprietary oligonucleotides to TOPIGEN.

TOPIGEN's pharmaceutical development program, based primarily on a unique and synergistic blend of antisense oligonucleotides, is directed toward the treatment of a host of inflammatory respiratory diseases. TOPIGEN's therapeutic platform is predicated on engaging multiple, not single, genes, which significantly broadens the anti-inflammatory response. The effectiveness of this approach has been amply borne out by proof-of-concept trials with TOPIGEN's lead product for the treatment of asthma.

Dowpharma, with its unique and well-grounded combination of oligonucleotide experience, process engineering capabilities and regulatory compliance record will provide a high-quality and reliable source of supply as oligonucleotide-based products move through the phases of clinical trials to commercial production. Dowpharma is currently providing its clients with both laboratory (campaigns to 100g) and mid-scale (campaigns to 5kg) cGMP oligonucleotide development and manufacturing capabilities. A commercial unit (~500kg annual capacity) will be on-line later in 2003.

This collaboration synergizes the strengths of both organizations - TOPIGEN's in the discovery and commercialization of novel therapeutics and Dowpharma in analytical and process development, and scale-up from the laboratory to cGMP commercial production.

Other news from the department research and development

Most read news

More news from our other portals

Discover the latest developments in battery technology!